Clinical Trial

Lorlatinib Compared with Concurrent/ Sequential Chemoradiotherapy in Stage III ALK Positive Lung Adenocarcinoma

Name: Lorlatinib Compared with Concurrent/ Sequential Chemoradiotherapy in Stage III ALK Positive Lung Adenocarcinoma — clinical trial record (NCT06858410)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 3

View on ClinicalTrials.gov →

Summary

The project is a Phase III, randomized, open-label, multicenter study in which approximately 36 patients with unresectable Stage III ALK positive Lung Adenocarcinoma will be randomized 1:1 to receive lorlatinib or concurrent/sequential platinum-based chemoradiotherapy

Trial Details

NCT Number	NCT06858410
Lead Sponsor	Guangdong Association of Clinical Trials
Conditions	Neoadjuvant Non-Small Cell Lung Cancer
Enrollment	36 participants
Start Date	2025-03
Primary Completion	2030-03 (estimated)
Study Completion	2030-08 (estimated)
Updated on ClinicalTrials.gov	2025-03-05